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Abstract
AIM: To investigate the survival of individuals with 
colorectal cancer (CRC) with inflammatory bowel dis-
ease (IBD-associated CRC) compared to that of indi-
viduals without IBD diagnosed with CRC.
METHODS: Epidemiologic, clinical, and follow-up data 
were obtained from the Colon Cancer Family Registry 
(Colon CFR). IBD-associated cases were identified from 
self-report of physician diagnosis. For a subset of partic-
ipants, medical records were examined to confirm self-
report of IBD. Cox proportional hazards regression was 
applied to estimate adjusted hazard ratios (aHR) and 
95%CI of mortality, comparing IBD-associated to non-
IBD-associated CRC, adjusted for age at CRC diagnosis, 
sex, Colon CFR phase, and number of prior endosco-
pies. Following imputation to complete CRC stage infor-
mation, adjustment for CRC stage was examined. 
RESULTS: A total of 7202 CRC cases, including 250 
cases of IBD-associated CRC, were analyzed. Over a 
twelve year follow-up period following CRC diagnosis, 
2013 and 74 deaths occurred among non-IBD associ-
ated CRC and IBD-associated CRC patients, respectively. 
The difference in survival between IBD-associated and 
non-IBD CRC cases was not statistically significant (aHR 
= 1.08; 95%CI: 0.85-1.36). However, the assumption of 
proportional hazards necessary for valid inference from 
Cox regression was not met over the entire follow-up 
period, and we therefore limited analyses to within five 
years after CRC diagnosis when the assumption of pro-
portional hazards was met. Over this period, there was 
evidence of worse prognosis for IBD-associated CRC 
(aHR = 1.36; 95%CI: 1.05-1.76). Results were similar 
when adjusted for CRC stage, or restricted to IBD con-
firmed in medical records.
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that IBD-associated CRC has a worse prognosis than 
non-IBD-associated CRC.
© 2013 Baishideng. All rights reserved.
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Core tip: Inflammatory bowel disease (IBD) - and more 
generally, inflammation - increases risk of colorectal 
cancer (CRC). Inflammation may also promote cancer 
progression and metastasis, and therefore, inflammation 
might be associated with shorter survival with CRC. This 
study examined whether CRC that occurs in patients 
with IBD has a worse prognosis than CRC in patients 
without IBD.
Adams SV, Ahnen DJ, Baron JA, Campbell PT, Gallinger S, 
Grady WM, LeMarchand L, Lindor NM, Potter JD, Newcomb 
PA. Survival after inflammatory bowel disease-associated 
colorectal cancer in the Colon Cancer Family Registry. World J 
Gastroenterol 2013; 19(21): 3241-3248  Available from: URL: 
http://www.wjgnet.com/1007-9327/full/v19/i21/3241.htm  DOI: 
http://dx.doi.org/10.3748/wjg.v19.i21.3241
INTRODUCTION
Inflammatory bowel disease (IBD), comprising ulcerative 
colitis (UC) and Crohn’s disease (CD), is an inflammatory 
disease affecting the gastrointestinal tract[1]. IBD is asso-
ciated with a substantial increase in the risk of  colorectal 
cancer (CRC), especially after 8-10 years of  active dis-
ease[2-4]. Implicated mechanisms include persistent acti-
vation of  cyclooxygenase-2 and nuclear factor kappa-B 
pathways and increased oxidative stress[5,6], leading IBD 
to be considered a model for understanding the role of  
chronic inflammation in CRC etiology[2,7].
IBD-associated CRCs have distinct molecular and 
clinical features compared to sporadic CRCs[6,8]. Specifi-
cally, CRC arising in association with IBD has an initia-
tion and progression sequence that differs from the 
canonical sequence of  adenoma-to-cancer characterizing 
sporadic CRC. Furthermore, IBD-associated CRC typi-
cally affects individuals at an earlier age than sporadic 
CRC, and the distribution of  histologic type and site 
within the colon may differ[6,8]. Despite these differences, 
the results of  many studies support the concept that in-
flammation at levels more subtle than that seen in IBD 
is associated with CRC risk[2]; in this model, inflamma-
tion acts primarily as a tumor-promoter following envi-
ronmental mutagenic insult. Non-IBD-associated CRC 
tumors show infiltration by inflammatory immune cells 
and elevated inflammatory cytokines[2]. Epidemiologically, 
circulating C-reactive protein, a marker of  inflammation, 
has been associated with increased risk[9,10], regular use of  
anti-inflammatory medication such as aspirin reduces risk 
of  CRC[11-15], and genetic variation in inflammatory path-
way genes may also modulate CRC risk[16,17]. Inflamma-
tion is also hypothesized to enhance metastasis in both 
IBD-associated and non-IBD-associated CRC[18]. 
Recent evidence suggests that the use of  non-steroidal 
anti-inflammatory drugs (NSAIDs) improves survival fol-
lowing CRC diagnosis[19,20]. From this it may be inferred 
that inflammation is involved in disease progression. If  
this is true, survival of  individuals with IBD-associated 
CRCs would be predicted to be worse than for those 
with sporadic CRCs. However, the evidence that IBD 
negatively affects the prognosis of  CRC comes primarily 
from small, hospital-based studies[21-24] and is inconsis-
tent. Among the largest previously published studies, one 
observed an approximately 20% higher risk of  mortality 
among UC-associated IBD patients compared to other 
CRC patients[25] and two others found no difference[26,27].
We accessed data from the large, multi-center Colon 
Cancer Family Registry (Colon CFR)[28] to compare the 
survival of  patients with IBD-associated CRC to those 
without IBD diagnosed with CRC.
MATERIALS AND METHODS
Study population: The Colon CFR
This study includes incident invasive CRC cases diag-
nosed between 1997 and 2009 registered with the Colon 
CFR, an international resource comprising seven sites 
that has been previously described in detail[28]. Case as-
certainment and recruitment methodology differed be-
tween Colon CFR centers and between registry phases 
(1997-2001 and 2002-2009)[28], and included population-
based recruitment in addition to targeted recruitment of  
CRC cases under age 50 or with a family history of  CRC. 
CRC cases associated with familial adenomatous polypo-
sis (n = 89) or Lynch syndrome (n = 1438) were exclud-
ed. Invasive CRC cases were eligible if  age, sex, and self-
reported IBD information was available; for the primary 
analysis both population-based cases and cases recruited 
through clinics associated with Colon CFR centers were 
included. Of  7297 eligible cases, 7202 records had com-
plete information on analytical covariates other than CRC 
stage, and were included in multivariate adjusted analyses.
Inflammatory bowel disease assessment
IBD prior to CRC diagnosis was assessed through self-
report during the Colon CFR baseline epidemiologic 
and medical history interview. Consecutive questions 
asked whether a participant had ever been told by doc-
tor that they had CD, UC, irritable bowel syndrome, or 
diverticulitis. The UC question included a statement that 
UC is not a stomach ulcer. Each affirmative answer was 
followed with a question ascertaining the participant’s age 
or calendar year in which the diagnosis was reported to 
the participant. Participants reporting either UC or CD 
diagnosis were counted as having IBD in the primary 
analysis. Participants reporting irritable bowel syndrome 
or diverticulitis were not considered to have IBD and in-
cluded with all other CRC cases.
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Clinical records at two Colon CFR centers, Ontario 
and Seattle, were reviewed for references to UC or CD. 
Of  169 self-reported IBD diagnoses from these centers, 
at least some medical or pathology records were available 
for 150 patients.
Covariate assessment
During the study interview, information was collected on 
family history of  CRC, medical history related to diges-
tive disease including endoscopy and hemoccult testing, 
height and weight, demographics, and lifestyle (e.g., ciga-
rette smoking, physical activity, and alcohol consump-
tion)[28]. A reference date of  2 years prior to CRC diagno-
sis was used to categorize participants’ exposures prior to 
diagnosis, except for endoscopy and hemoccult testing. 
Hemoccult testing was categorized as never, 1-4, or 5 or 
more total tests. Similarly the total lifetime number of  re-
ported endoscopies (colonoscopies and sigmoidoscopies) 
was categorized as none or 1, 2, or 3 or more.
Tumor characteristics
Cancer stage, histologic type (i.e., adenocarcinoma, mu-
cinous adenocarcinoma, signet ring cell carcinoma), and 
anatomic site of  the tumor were obtained from registry 
or pathology reports[28]. For analysis, tumors in the cecum, 
ascending colon, hepatic flexure, transverse colon, and 
splenic flexure (ICD-O-3 codes C180, C182-185) were 
considered proximal; tumors in the descending colon 
(C186) and sigmoid colon (C187) were grouped as distal 
colon tumors; and rectosigmoid junction (C199), rectum 
(C209), and overlapping lesion of  the anus and rectum 
(C218) were considered rectal tumors. Stage information 
was obtained by Colon CFR centers from the Surveillance 
Epidemiology and End Results (SEER) registry (Seattle 
and Hawaii) or medical records and pathology review (all 
other centers). Records included American Joint Commit-
tee on Cancer staging on tumor extent (T-stage), lymph 
node positivity (N-stage; number of  nodes positive for 
malignant cells), and the presence of  distant metastases 
(M-stage). From these indices, stage was summarized as lo-
cal, regional, or distant following SEER guidelines. Micro-
satellite instability (MSI) status was characterized for 4422 
cases with available tumor samples in the Colon CFR, 
combining the results of  genetic analysis of  a 10-marker 
panel and immunohistochemicalstaining of  DNA mis-
match repair proteins as previously described[28-33]. 
Imputation of stage of CRC
Of 7202 cases eligible for this analysis, 4450 (62%) initially 
could not be categorized in a SEER summary stage. Of  
these, 4343 could not be classified in part because of  miss-
ing M-stage information, primarily because ascertaining 
distant metastases required medical records not acces-
sible at all Colon CFR centers. However, 2859 of  these 
cases without M-stage information included T- or N-stage 
information. Missing stage information was imputed in 
two steps. First, cases without M information but with N 
information indicating that no lymph nodes tested positive 
for malignant cells were coded as having no distant me-
tastases. If  T-stage information was also available, SEER 
summary stage was updated to local or regional. In total 
1509 of  4450 cases (34%) originally missing SEER sum-
mary stage were completed through this direct imputation.
Following direct imputation, multiple imputation with 
chained equations was used to complete the remaining 
cases missing stage information[34]. T-stage (T1-3, T4) 
and N-stage (N0, N > 0) were reduced to dichotomous 
variables. Fifty datasets were generated with T, N and M 
imputed using chained logistic regression based on all 
variables considered in the primary survival analysis (see 
below), and additional potential predictors of  stage: time 
at risk, vital status, delay between CRC diagnosis and 
Colon CFR enrollment, histologic type, partial colectomy 
(ever, never, missing), and tumor site (proximal, distal, 
rectal, overlapping/NOS). Imputation regression ex-
cluded cases with incomplete information in one or more 
predictors (n = 889). In total, 6313 cases were included in 
multiple imputation regression; T, N or M were imputed 
for 1677, 1697 and 2438 cases, respectively. Following 
imputation, SEER summary stage was derived from im-
puted T, N and M following SEER coding[35,36]. Together 
with cases whose records originally included SEER sum-
mary stage or were completed with direct imputation, de-
scribed above, a total of  6809 cases with SEER summary 
stage were included in analyses involving stage. 
Vital status
Vital status was updated at each Colon CFR center 
through linkage to population-based tumor registries and 
death indices, in addition to active follow-up 4-5 years 
after initial enrollment and routine contact with enrollees 
and family members[28]. 
Ethical considerations
Each Colon CFR center Institutional Review Board/eth-
ics board approved all study protocols and all participants 
provided informed consent. 
Statistical analysis
Cox proportional hazards regression was used to estimate 
adjusted hazard ratios (aHRs) of  death from any cause 
with 95%CIs. Time at risk was measured in days from 
CRC diagnosis, with participants entering observation on 
the date of  Colon CFR baseline interview. Participants 
alive at the most recent time of  confirmed contact were 
censored at that date. Parallel analyses were completed 
for the full follow-up time, and with administrative cen-
soring of  all participants 5 years after CRC diagnosis. The 
proportional hazard assumption was examined graphi-
cally and by allowing the variable representing IBD status 
to interact with the logarithm of  failure time, and testing 
the significance of  the time-varying factor[37].
To adjust for age at CRC diagnosis, participants were 
divided into approximate quartiles of  age (cut-points 
at 47, 56 and 65 years) and a piecewise linear model of  
hazard of  death was constructed. Additional a priori can-
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copy. Colon CFR center, NSAID use, BMI, education, 
race, smoking, hemoccult tests, and family history were 
omitted from final statistical models because inclusion 
did not appreciably change aHRs associated with IBD. 
CRC stage, when included, was parameterized as SEER 
summary stage (localized, regional, or distant disease).
RESULTS
Of  7202 eligible CRC patients, 250 (3.5%) reported a 
physician’s diagnosis of  IBD (Table 1). IBD-associated 
CRC patients were younger at CRC diagnosis than non-
IBD cases. In addition, IBD-associated CRC patients 
were less likely to have ever regularly smoked cigarettes, 
and were leaner on average than other patients with CRC. 
IBD-associated CRC patients were much more likely than 
sporadic CRC patients to be white, report a family history 
of  CRC, or have had multiple endoscopies.
Compared to non-IBD cases, a larger proportion of  
IBD-associated CRC patients were diagnosed with tumors 
in the proximal colon (Table 1). Among tumors assayed 
for MSI, no difference in the distribution of  MSI between 
IBD-associated and other CRC was observed.The dis-
tribution of  SEER summary stage differed only slightly 
between IBD-associated CRC and other CRC following 
completion of  missing stage information with multiple 
imputation. However, a more pronounced, but not statisti-
cally significant, difference in stage distribution between 
IBD-associated and sporadic CRC was noted among 
patients diagnosed before age 50 year; in this age group, 
24% of  non-IBD associated CRC cases were diagnosed 
after distant metastases has occurred, compared to 18% of  
IBD-associated CRC cases (not shown; χ2 test P > 0.15).
Over a total follow-up of  12.2 years (median of  4.6 
years), 2013 and 74 deaths were reported among non-
IBD-associated and IBD-associated CRC cases, respec-
tively. Results of  Cox proportional hazards regression 
using the full follow-up period indicated no association 
between IBD and risk of  mortality from any cause (Figure 
1 and Table 2). 
Graphical inspection of  the Kaplan-Meier survival 
curve (Figure 1) and formal testing of  time-varying coef-
ficients (not shown), indicated that the proportional haz-
ards assumption was violated by the variable representing 
IBD status. Ending follow-up at no later than 5 years 
following diagnosis for all participants resolved the pro-
portional hazards violation based on time-varying models 
(not shown). 
Results from analyses including only the 5 years fol-
lowing diagnosis, but otherwise identical to analysis across 
the entire follow-up time, showed that IBD-associated 
CRC patients were at 36% (95%CI: 5%-76%) higher risk 
of  death (Figure 1 and Table 2). Following imputation of  
CRC stage, additional adjustment for stage left resulting 
aHR estimates largely unchanged.
Medical and pathology records of  169 eligible cases 
enrolled at the Seattle and Ontario CFR centers were 
reviewed; for 14 IBD-associated CRC cases no records 
didate adjustment variables were Colon CFR phase of  
enrollment (1997-2001 or 2002-2009), Colon CFR center, 
sex, cigarette smoking history, use of  NSAIDs, educa-
tion, race, body mass index (BMI), first degree family his-
tory of  CRC, and utilization of  hemoccult tests or endos-
  Characteristics Inflammatory bowel disease P  value
No Yes
(n  = 6952) (n  = 250)
  Age at CRC diagnosis (yr) < 0.001
     < 47 1731 (25)   98 (39)
     47-55 1791 (26)   68 (27)
     56-65 1803 (26)   42 (17)
     > 65 1627 (23)   42 (17)
  Female 3515 (51) 133 (53)     0.4
  Lifetime endoscopies < 0.001
     None or one 2697 (39)   40 (16)
     Two 2004 (29)   51 (20)
     Three or more 2251 (32) 159 (64)
  Colon CFR recruitment phase     0.4
     Ⅰ (1997-2001) 4310 (62) 161 (64)
     Ⅱ (2002-2009) 2642 (38)   89 (36)
  Colon CFR center < 0.01
     Ontario, Canada 1775 (26)   89 (36)
     Southern California, United States 1551 (22)   39 (16)
     Melbourne, Victoria, Australia   718 (10) 20 (8)
     Hawaii, United States 348 (5)   6 (2)
     Mayo Clinic, MI, United States 499 (7) 16 (6)
     Seattle, WA, United States 2061 (30)   80 (32)
  Education1     0.8
     Secondary or less 3367 (49) 123 (50)
     More than secondary 3518 (51) 124 (50)
  Cigarette smoking history1,2     0.02
     Never 3022 (44) 130 (52)
     Current 1259 (18)   44 (18)
     Former 2650 (38)   75 (30)
  Race1 < 0.01
     White 5033 (74) 200 (83)
     Other 1769 (26)   42 (17)
  BMI (kg/m2)1,2 < 0.01
     ≤ 23.6 1685 (25)   85 (34)
     23.7-26.5 1710 (25)   59 (24)
     26.6-30.3 1726 (25)   51 (21)
     ≥ 30.4 1739 (25)   53 (21)
  Regular NSAID user1,2     0.7
     Yes 2719 (40)   95 (39)
     No 4159 (60) 151 (61)
  1st degree family history of CRC 1495 (22)   35 (14) < 0.01
  Tumor site < 0.01
     Proximal colon 2346 (34) 109 (44)
     Distal colon or rectum 4276 (62) 136 (54)
     Overlapping/not specified 328 (5)   5 (2)
  Microsatellite instability1     0.1
     None or low 3743 (88) 150 (87)
     High   507 (12)   22 (12)
  CRC stage at diagnosis1,3     0.4
     Local 3088 (47) 110 (46)
     Regional 2441 (37)   98 (40)
     Distant 1080 (16)   34 (14)
Table 1  Participant characteristics of colorectal cancer cases 
at enrollment in the Colon Cancer Family Registry according 
to self-reported diagnosis of inflammatory bowel disease  n (%)
1Numbers do not sum to total due to missing values; 22 years prior to 
colorectal cancer (CRC) diagnosis; 3Mean of 50 imputed datasets. Colon 
CFR: Colon Cancer Family Registry; NSAID: Non-steroidal anti-inflamma-
tory drugs; BMI: Body mass index.
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were available for review, for 43 only pathology reports 
or death certificates were available, and for 107 pathology 
and at least partial medical records were available. Dur-
ing review, 81 of  these 169 self-reported IBD diagnoses 
were confirmed. When proportional hazards regression 
analysis was repeated including confirmed IBD diagnoses 
and non-IBD-associated CRC only from the Seattle and 
Ontario Colon CFR centers, and thus excluding uncon-
firmed self-reported IBD from analyses, results suggested 
that IBD was associated with a 52% (95%CI: 0%-130%) 
higher risk of  mortality following CRC diagnosis (Table 2). 
In exploratory sub-group analyses of  survival through 
5 years post-CRC diagnosis, the association between 
IBD and risk of  death did not vary by MSI status of  the 
tumor (not shown). However, IBD was more strongly as-
sociated with risk of  death among patients with distal or 
rectal CRC tumors (aHR = 1.62, 95%CI: 1.17-2.26) than 
among patients with tumors in the proximal colon (aHR 
= 0.98; 95%CI: 0.64-1.50), although the interaction be-
tween IBD and tumor site was not statistically significant 
(P = 0.06). Survival also did not differ by duration of  
IBD prior to CRC diagnosis (< 8 years IBD, aHR = 1.38, 
95%CI: 0.96-1.99; ≥ 8 years IBD, aHR = 1.38, 95%CI: 
0.96-2.00). Patients reporting only CD were apparently 
at higher risk of  mortality than those with UC only, al-
though the difference was not statistically significant (CD, 
aHR = 1.74, 95%CI: 1.09-2.79; UC, aHR = 1.18, 95%CI: 
0.85-1.63, P = 0.16). 
Restriction of  analysis to 4144 population-based cases 
enrolled during phase Ⅰ did not appreciably alter the as-
sociation between IBD and hazard of  mortality within 5 
years of  CRC diagnosis (aHR = 1.47, 95%CI: 1.08-2.01). 
Incorporation of  probability weights based on the sam-
pling scheme of  the Colon CFR[28] also did not change 
results of  death, IBD compared to non-IBD-associated 
CRC (aHR = 1.62, 95%CI: 1.04-2.54).
DISCUSSION
We observed a higher risk of  death from any cause among 
patients with IBD-associated CRC compared to those 
with non-IBD-associated CRC when attention was re-
stricted to the first five years following CRC diagnosis. 
The increase in risk was of  borderline statistical signifi-
cance. However, no increase in risk of  death was seen 
when all available follow-up data were analyzed. The 
violation of  the proportional hazard assumption made 
the analysis using all available follow-up time difficult to 
interpret; in contrast, the period within 5 years following 
CRC diagnosis showed no violations of  the proportional 
hazards assumption.
CRC stage at diagnosis is a strong predictor of  surviv-
al, and IBD patients may undergo surveillance designed 
to detect CRC at early stages. Therefore, we compared 
CRC stage distribution between cases with and without 
IBD, and conducted stage-adjusted survival analyses. Our 
results suggest that IBD-associated CRC is only slightly 
more frequently diagnosed at local or regional stage than 
non-IBD-associated CRC. This may be due to active 
endoscopic surveillance for CRC among IBD patients, 
consistent with earlier reports[38]. We observed that the 
shift in stage distribution was larger, but not statistically 
significant, among CRC patients diagnosed prior to age 
50 years; this group would generally not receive screening 
endoscopy in the absence of  gastrointestinal symptoms 
or a strong family history of  CRC. 
n Deaths aHR1 (95%CI) n Deaths aHR2 (95%CI) n Deaths aHR1,3 (95%CI)
  Complete follow-up
     No IBD 6952 2013 Ref. 6567 1926 Ref. 3836 1322 Ref.
     IBD   250     74 1.08 (0.85-1.36)   242     71 1.09 (0.85-1.40)     81     26 1.20 (0.81-1.79)
     P value       0.54        0.48     0.36
  5-yr follow-up
     No IBD 6903 1372 Ref. 6526 1320 Ref. 3801   871 Ref.
     IBD   249     63 1.36 (1.05-1.76)   241     60 1.34 (1.02-1.77)     81     24 1.52 (1.00-2.30)
     P value       0.018        0.037     0.048
Table 2  Adjusted hazard ratios and 95%CI for death, either with complete available time-at-risk or with follow-up ended 5 years 
after colorectal cancer diagnosis
1Adjusted for age, recruitment phase, sex, and endoscopy; 2Additional adjustment for surveillance epidemiology and end results summary stage (local, re-
gional, distant); 3Inflammatory bowel disease (IBD) confirmed from medical and pathology records at Seattle and Ontario centers only, non-IBD associated 
















P  = 0.019
P  = 0.54
0                            5                           10                          15
                           Years since CRC diagnosis
Figure 1  Adjusted survival probability for non-inflammatory bowel dis-
ease-associated (solid line) and inflammatory bowel disease-associated 
colorectal cancer (dashed line). P values are from Wald test of coefficient of 
inflammatory bowel disease from Cox regression. CRC: Colorectal cancer.
Adams SV et al . Survival after IBD-associated colorectal cancer
3246 June 7, 2013|Volume 19|Issue 21|WJG|www.wjgnet.com
When we repeated survival analysis adjusted for stage, 
our results still suggested increased risk of  mortality 
among IBD-associated CRC patients. Further exploration 
revealed that after adjustment for the lifetime number of  
endoscopic procedures, adjustment for SEER summary 
stage did not substantially alter the aHR associated with 
IBD, as would be expected if  endoscopy utilization was 
an important determinant of  CRC stage at diagnosis. 
Examination of  our multiple imputation model for CRC 
stage confirmed that endoscopy was among the strongest 
predictors of  CRC stage. Thus, our results indicate that 
survival was poorer for IBD-associated CRC patients than 
for other CRC patients diagnosed at the same SEER stage.
Our results are consistent with reports from several 
previous studies[24,39] including the largest previous pop-
ulation-based studies of  this topic[25,40], which included a 
similar number of  UC- and CD-associated CRC cases. 
These studies reported about 20% or 50% higher mortal-
ity among UC-associated CRC patients[25] and CD-asso-
ciated CRC patients[40], respectively, compared to other 
CRC patients, adjusted for CRC stage. A large Japanese 
study observed worse prognosis for UC-associated CRC 
but the relationship was restricted to stage Ⅲ CRC[27]. In 
contrast with our results, a relatively large (n = 290 IBD-
associated CRC cases) clinic-based study did not observe 
differential risk of  death between IBD-associated and 
other CRC cases, possibly because of  the clinical basis 
of  the study[26]. Thus, our overall results, based on a set 
of  relatively unselected cases and confirmed in the pop-
ulation-based portion of  the Colon CFR, agree with the 
population-based results[25,40], and strengthen the evidence 
that the prognosis for IBD-associated CRC is worse than 
for non-IBD-associated CRC.
Our study has additional important methodological 
strengths. Approximately 57% of  participants in this study 
were drawn from Colon CFR centers that utilize population-
based case ascertainment strategies. Therefore, our results 
are likely to provide more general insight into the survival of  
IBD-associated CRC than clinic-based case series. Although 
our sample size was limited by the rarity of  both IBD and 
CRC, the large, multi-site Colon CFR included a broad spec-
trum of  CRC. Furthermore, because of  the size of  the Co-
lon CFR, the cases in this study were recruited over 12 years, 
in comparison to previous reports that required 20 or more 
years to recruit a comparable number[25,27].
An important limitation of  this study was our reliance 
on participant report of  either UC or CD. We believe 
that our inability to confirm about 50% of  self-reported 
UC or CD in patients from Ontario and Seattle resulted 
mainly from lack of  access to complete medical records 
prior to CRC diagnosis. Although we expected IBD to be 
noted on pathology or medical records related to CRC 
diagnosis, we cannot be sure why information might be 
missing; the self-report of  UC or CD might be incor-
rect, or the limited records available for review may be 
incomplete. Nonetheless, when we restricted analysis to 
confirmed IBD cases, removing unconfirmed IBD from 
analysis, the association between IBD-associated CRC and 
risk of  mortality was strengthened. This could be because 
we successfully reduced misclassification of  IBD. Alterna-
tively, IBD confirmed in medical records may have been, 
on average, more severe than unconfirmed IBD, perhaps 
because available medical records were those related to 
CRC diagnosis.
Because we lacked detailed IBD-specific medical re-
cords, we were also unable to determine how medications 
such as 5-aminosalicyclic acid (5-ASA) used to treat IBD 
may have affected our results. In some studies, 5-ASA use 
has been associated with a reduced risk of  CRC in IBD 
patients[41,42], and IBD patients who are never diagnosed 
with CRC are not included in our analysis. Like other anti-
inflammatory drugs[19,20], 5-ASA treatment prior to CRC 
may reduce the risk of  CRC mortality, and this may ac-
count in part for the relatively small difference in survival 
we observed between IBD-associated and sporadic CRC.
We also lacked specific cause of  death information 
for deaths recorded outside of  the Seattle, Ontario, and 
Mayo Clinic Colon CFR centers. However, at these cen-
ters, CRC was the underlying cause of  death for 24 of  
31 (77%) IBD-associated CRC patients and 499 of  651 
(77%) of  non-IBD CRC patients who died within 5 years 
of  CRC diagnosis. Therefore, it is likely that most of  the 
deaths included in the 5-year analysis across all Colon 
CFR centers were due to CRC, and differences in cause 
of  death between IBD-associated and other CRC is un-
likely to have influenced our results.
Finally, our sample size was limited to fully evaluate 
this association. IBD is associated with a strong increase 
in CRC risk[2,3,43], and we noted a higher prevalence of  
IBD, approximately 3.5%, among CRC cases than would 
be expected in the underlying population in which these 
CRC cases arose. For example, the prevalence of  IBD 
in the United States is less than 1%[44,45]. However, the 
number of  IBD-associated CRC cases in our study is ap-
proximately equal to the largest previous study compar-
ing survival with non-IBD-associated CRC[25]. Nonethe-
less, sparse numbers certainly hindered our analysis and 
suggest that cautious interpretation is warranted. Future 
progress may perhaps be achieved by combining multiple 
populations through pooled or meta-analyses.
Our observation that IBD-associated CRC appears to 
have a worse prognosis than non-IBD-associated CRC, 
even when stage at diagnosis is taken into account, is 
consistent with evidence that inflammation negatively im-
pacts CRC survival[19,20]. The mechanisms through which 
this may occur remain to be determined.
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